KPIs & Operating Metrics(New)

Balance Sheet

Accounts Payables Accumulated Expenses Assets Buildings Cash & Current Investments Cash & Equivalents Common Equity Construction in Progress Curent Deferred Tax Liability Current Assets Current Deferred Revenue Current Deferred Tax Assets Current Taxes Dividends payables Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Land & Improvements Liabilities and Shareholders Equity Long-Term Deferred Tax Long-Term Investments Minority Interest Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Pension Preferred Shares Prepaid Assets Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Daily Values

Growth Metrics

Others

Pfizer (PFE) Liabilities from Discontinued Operations (2018 - 2019)

Historic Liabilities from Discontinued Operations for Pfizer (PFE) over the last 6 years, with Q4 2019 value amounting to $2.4 billion.

Pfizer's Liabilities from Discontinued Operations rose 2767.2% to $2.4 billion in Q4 2019 from the same period last year, while for Dec 2019 it was $2.4 billion, marking a year-over-year increase of 2767.2%. This contributed to the annual value of $2.4 billion for FY2019, which is 2767.2% up from last year.
Per Pfizer's latest filing, its Liabilities from Discontinued Operations stood at $2.4 billion for Q4 2019, which was up 2767.2% from $2.0 billion recorded in Q2 2019.
Pfizer's Liabilities from Discontinued Operations' 5-year high stood at $2.4 billion during Q4 2019, with a 5-year trough of $1.9 billion in Q4 2018.